Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "ADC"

156 News Found

Shilpa Medicare Jadcherla facility gets GMP certification from Russia
Policy | May 29, 2021

Shilpa Medicare Jadcherla facility gets GMP certification from Russia

The GMP certificate is valid for three years until April 2024.


Altimmune expands AdCOVID manufacturing collaboration with Lonza
News | March 13, 2021

Altimmune expands AdCOVID manufacturing collaboration with Lonza

AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.


Cohance Lifesciences appoints Yann D'Herve as CEO of CDMO Business
People | July 29, 2025

Cohance Lifesciences appoints Yann D'Herve as CEO of CDMO Business

His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors


Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
News | June 24, 2025

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

First and only TROP2-directed therapy approved in the US for the treatment of lung cancer


Sanner commences manufacturing critical injection-molded components in USA
Packaging | June 20, 2025

Sanner commences manufacturing critical injection-molded components in USA

The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space


Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites
News | June 09, 2025

Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021


Keytruda plus Trodelvy reduced risk of disease progression by 35% V/s Keytruda plus cchemothrapy in first-line PD-L1+ TNBC
Diagnostic Center | June 02, 2025

Keytruda plus Trodelvy reduced risk of disease progression by 35% V/s Keytruda plus cchemothrapy in first-line PD-L1+ TNBC

First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC


Merck withdraws Biologics License Application for Patritumab Deruxtecan
Drug Approval | May 30, 2025

Merck withdraws Biologics License Application for Patritumab Deruxtecan

The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance


Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025
News | May 23, 2025

Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025

Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025


AstraZeneca's enhertu improved pCR in early-stage breast cancer
News | May 07, 2025

AstraZeneca's enhertu improved pCR in early-stage breast cancer

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care